ARGENX SE (1AE.DE) Stock Price & Overview
FRA:1AE • NL0010832176
The current stock price of 1AE.DE is 616.2 EUR. Today 1AE.DE is down by -2.62%. In the past month the price decreased by -13.16%.
1AE.DE Key Statistics
- Market Cap
- 38.133B
- P/E
- 36.46
- Fwd P/E
- 25.50
- EPS (TTM)
- 16.90
- Dividend Yield
- N/A
1AE.DE Stock Performance
1AE.DE Stock Chart
1AE.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1AE.DE.
1AE.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1AE.DE. While 1AE.DE has a great health rating, its profitability is only average at the moment.
1AE.DE Earnings
On February 26, 2026 1AE.DE reported an EPS of 8.02 and a revenue of 1.29B. The company beat EPS expectations (20.47% surprise) and missed revenue expectations (-2.45% surprise).
1AE.DE Forecast & Estimates
25 analysts have analysed 1AE.DE and the average price target is 879.44 EUR. This implies a price increase of 42.72% is expected in the next year compared to the current price of 616.2.
For the next year, analysts expect an EPS growth of 42.94% and a revenue growth 38.91% for 1AE.DE
1AE.DE Groups
Sector & Classification
1AE.DE Financial Highlights
Over the last trailing twelve months 1AE.DE reported a non-GAAP Earnings per Share(EPS) of 16.9. The EPS increased by 1028.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.12% | ||
| ROA | 18.01% | ||
| ROE | 21.2% | ||
| Debt/Equity | 0.01 |
1AE.DE Ownership
1AE.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.4 | 38.12B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.515B | ||
| ABVX | ABIVAX SA | N/A | 8.129B | ||
| 2X1 | ABIVAX SA | N/A | 8.097B | ||
| GXE | GALAPAGOS NV | N/A | 1.831B | ||
| GLPG | GALAPAGOS NV | N/A | 1.827B | ||
| NANO | NANOBIOTIX | N/A | 1.328B | ||
| IVA | INVENTIVA SA | N/A | 1.098B | ||
| 6IV | INVENTIVA SA | N/A | 1.098B | ||
| PHIL | PHILOGEN SPA | 18.09 | 663.748M | ||
| XUP | GENFIT | N/A | 468.027M | ||
| GNFT | GENFIT | 831.37 | 435.275M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1AE.DE
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
IPO: 2014-07-10
ARGENX SE
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND NL
Employees: 1599
Phone: 31763030
ARGENX SE / 1AE.DE FAQ
What does ARGENX SE do?
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Can you provide the latest stock price for ARGENX SE?
The current stock price of 1AE.DE is 616.2 EUR. The price decreased by -2.62% in the last trading session.
Does ARGENX SE pay dividends?
1AE.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1AE stock?
1AE.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the valuation of ARGENX SE (1AE.DE) based on its PE ratio?
The PE ratio for ARGENX SE (1AE.DE) is 36.46. This is based on the reported non-GAAP earnings per share of 16.9 and the current share price of 616.2 EUR.
Would investing in ARGENX SE be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1AE.DE.